Cinacalcet HCl: A Novel Treatment for Secondary Hyperparathyroidism Caused by Chronic Kidney Disease

Journal of Renal Nutrition

Volumn 16, Issue 3, 2006, Pages 253-258

  Torres, Pablo Ureña ^a  

^a Clinique de l'Orangerie Aubervilliers   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; NAPHTHALENE DERIVATIVE; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ARTICLE; CHEMISTRY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; HYPERCALCEMIA; KIDNEY TRANSPLANTATION; METABOLISM; PARATHYROID GLAND; PARATHYROID TUMOR; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM;

CALCIUM; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; NAPHTHALENES; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; PHOSPHATES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CALCIUM-SENSING; RENAL DIALYSIS; VITAMIN D;

EID: 33745699190     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2006.04.010     Document Type: Article

References (48)

1. Young E.W., Akiba T., Albert J.M., et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 (2004) 34-38
2. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12 (2001) 2131-2138
3. Gagné E.R., Ureña P., Leite-Silva S., et al. Short and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 3 (1992) 1008-1017
4. Brown E.M., Gamba G., Riccardi D., et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366 (1993) 575-580
5. Nemeth E.F., Steffey M.E., Hammerland L.G., et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 95 (1998) 4040-4045
6. Slatopolsky E., Gradowska L., Kashemsant C., et al. The control of phosphate excretion in uremia. J Clin Invest 45 (1966) 672-677
7. Shigematsu T., Kazama J.J., Yamashita T., et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44 (2004) 250-256
8. Ureña P., Kubrusly M., Mannstadt M., et al. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 45 (1994) 605-611
9. Silver J., Kilav R., and Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 283 (2002) F367-F376
10. Fukuda N., Tanaka H., Tominaga Y., et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92 (1993) 1436-1443
11. Tominaga Y., Tanaka Y., Sato K., et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 13 (1997) 78-86
12. Gogusev J., Duchambon P., Hory B., et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51 (1997) 328-336
13. Kifor O., Moore Jr. F.D., Wang P., et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81 (1996) 1598-1606
14. Tominaga Y., Kohara S., Namii Y., et al. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 20 (1996) 744-750
15. Tominaga Y., Sato K., Tanaka Y., et al. Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. Clin Nephrol 44 suppl 1 (1995) S42-S47
16. Arnold A., Brown M., Ureña P., et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95 (1995) 2047-2054
17. Massry S.G., and Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14 (1994) 219-231
18. Rostand S.G., and Drueke T.B. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56 (1999) 383-392
19. Amann K., and Ritz E. Cardiac disease in chronic uremia. Pathophysiology. Adv Ren Replace Ther 4 (1997) 212-224
20. Amann K., Tornig J., Flechtenmacher C., et al. Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia. Evidence for a permissive action of PTH. Nephrol Dial Transplant 10 (1995) 2043-2048
21. Kosch M., Hausberg M., Vormbrock K., et al. Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res 47 (2000) 813-818
22. London G.M., Guerin A.P., Marchais S.J., et al. Arterial media calcification in end-stage renal disease. Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 (2003) 1731-1740
23. Rodriguez M., Nemeth E., and Martin D. The calcium-sensing receptor. A key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 288 (2005) F253-F264
24. Ramirez J.A., Goodman W.G., Gornbein J., et al. Direct in vivo comparison of calcium regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 76 (1993) 1489-1494
25. Kessler A., Faure H., Petrel C., et al. N(2)-benzyl-N(1)-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues. Development of calindol as a new calcimimetic acting at the calcium sensing receptor. Bioorg Med Chem Lett 14 (2004) 3345-3349
26. Petrel C., Kessler A., Dauban P., et al. Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 279 (2004) 18990-18997
27. Antonsen J.E., Sherrard D.J., and Andress D.L. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 53 (1998) 223-227
28. Goodman W.G., Frazao J.M., Goodkin D.A., et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58 (2000) 436-445
29. Mimpara (Cinacalcet) SPC (2004), Amgen, Breda, the Netherlands
30. Sensipar (Cinacalcet HCl) Prescribing Information (2004), Amgen, Breda, the Netherlands
31. Coburn J., Barri Y., Turner S., et al. Single doses of the calcimimetic AMG-073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 11 (2000) 573A
32. Ureña P., Basile C., Grateau G., et al. Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia. A prospective study. Kidney Int 36 (1989) 120-126
33. VanAbel M., Hoederop J.G.J., and VanLeeuwen J.P.T.M. Down-regulation of Ca2+ transporters in kidney and duodenum by the calcimimetic compound NPS R-467. J Am Soc Nephrol 14 (2003) SA-P073, (abstr)
34. Drueke T., Cunningham J., Goodman W., et al. Short-term treatment of secondary hyperparathyroidism (SHTP) with the calcimimetic agent AMG 073. J Am Soc Nephrol 12 (2001) 764A
35. Block G.A., Martin K.J., deFrancisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 (2004) 1516-1525
36. Urena P., Legoupil N., deVernejoul M.C., et al. Sustained control of uraemic secondary hyperparathyroidism (SHPT) after three years of treatment with the calcimimetic cinacalcet HCL. A single centre experience (2003) Poster presented at the 40th ERA-EDTA World Congress of Nephrology, Berlin
37. Quarles L.D., Sherrard D.J., Adler S., et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14 (2003) 575-583
38. Lindberg J.S., Moe S.M., Goodman W.G., et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int 63 (2003) 248-254
39. Mittman N., Finkelstein F., Culleton B., et al. Cinacalcet HCl (Sensipar) for the management of secondary hyperparathyroidism in study patients receiving peritoneal dialysis. J Am Soc Nephrol 15 (2004) 280A (abstr)
40. Bushinsky D.A. Cinacalcet HCl in secondary hyperparathyroidism. Official Evening Symposium. ASN 2004 (2004), American Society of Nephrology, St. Louis, Missouri October 27 to November 1
41. Moe S.M., Chertow G.M., Coburn J.W., et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67 (2005) 760-771
42. Moe S.M., Cunningham J., Bommer J., et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20 (2005) 2186-2193
43. Cunningham J., and Chertow G. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 (2005) 1793-1800
44. Evenepoel P., Claes K., Kuypers D., et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation. A single-centre study. Nephrol Dial Transplant 19 (2004) 1281-1287
45. Kruse A.E., Eisenberger U., Frey F.J., et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 20 (2005) 1311-1314
46. Serra A.L., Schwarz A.A., Wick F.H., et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 20 (2005) 1315-1319
47. Collins M.T., Skarulis M.C., Bilizkian J.P., et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83 (1998) 1080-1082
48. Rubin M.R., Sliney J., Silverberg S.J., et al. Clinical course of 10 patients with inoperable parathyroid carcinoma treated with the calcimimetic cinacalcet HCl. J Bone Miner Res 19 (2004) S103 (abstr F497)